State of Tennessee Treasury Department lessened its stake in Nektar Therapeutics (NASDAQ:NKTR) by 9.0% in the 4th quarter, HoldingsChannel reports. The fund owned 122,920 shares of the biopharmaceutical company’s stock after selling 12,185 shares during the quarter. State of Tennessee Treasury Department’s holdings in Nektar Therapeutics were worth $7,341,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Meeder Asset Management Inc. purchased a new stake in Nektar Therapeutics in the 4th quarter worth $121,000. SeaCrest Wealth Management LLC purchased a new stake in Nektar Therapeutics in the 4th quarter worth $200,000. Kovack Advisors Inc. purchased a new stake in Nektar Therapeutics in the 4th quarter worth $240,000. Sicart Associates LLC purchased a new stake in Nektar Therapeutics in the 4th quarter worth $245,000. Finally, Eqis Capital Management Inc. purchased a new stake in Nektar Therapeutics in the 4th quarter worth $254,000. 96.23% of the stock is owned by institutional investors.
In other news, CAO Jillian B. Thomsen sold 2,545 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $82.94, for a total transaction of $211,082.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Stephen K. Doberstein sold 2,426 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $82.94, for a total transaction of $201,212.44. Following the sale, the senior vice president now directly owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The disclosure for this sale can be found here. Insiders have sold 222,781 shares of company stock valued at $14,884,901 in the last ninety days. Insiders own 5.44% of the company’s stock.
Shares of Nektar Therapeutics (NASDAQ NKTR) opened at $90.05 on Wednesday. Nektar Therapeutics has a 1-year low of $12.50 and a 1-year high of $99.02. The stock has a market cap of $14,524.58, a price-to-earnings ratio of -125.07 and a beta of 2.04. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91.
COPYRIGHT VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Position Reduced by State of Tennessee Treasury Department” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3228896/nektar-therapeutics-nktr-position-reduced-by-state-of-tennessee-treasury-department.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.